Correspondence 0001654954-23-009659 from Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics, Inc.
Date: July 25, 2023 · CIK: 0001853816 · Accession: 0001654954-23-009659

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-273170

Date

July 25, 2023

Author

Form

CORRESP

Company

Dermata Therapeutics, Inc.

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance CIK No.: 0001853816 Acceleration Request Requested Date: July 27, 2023 Requested Time: 4:30 PM, Eastern Time

Dear Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Dermata Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) on the “Requested Date” at the “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via a telephone call to the staff of the Division of Corporation Finance of the Commission.

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions.

Sincerely,
DERMATA THERAPEUTICS, INC.

Show Raw Text

CORRESP
1
filename1.htm

drma_corresp.htm

 July 25, 2023

 VIA EDGAR

 United States Securities and Exchange Commission

 Division of Corporation Finance

 Mail Stop 4720

 100 F Street, N.E.

 Washington, D.C. 20549

         Re:

   Dermata Therapeutics, Inc.

 Registration Statement on Form S-1

 File No. 333-273170

 CIK No.: 0001853816

 Acceleration Request

 Requested Date: July 27, 2023

 Requested Time: 4:30 PM, Eastern Time

 Dear Ladies and Gentlemen:

 Pursuant to Rule 461 under the Securities Act of 1933, as amended, Dermata Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) on the “Requested Date” at the “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via a telephone call to the staff of the Division of Corporation Finance of the Commission.

 Please call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions.

   Sincerely,

   DERMATA THERAPEUTICS, INC.

   By:

   /s/ Gerald T. Proehl

   Name:

   Gerald T. Proehl

   Title:

   Chief Executive Officer

SecProbe.io